November 26, 202436Kr Heavyweight Released"WISE2024 Business King of the Year Corporate Rankings",METiS TechBio (METiS Pharmaceuticals) as an outstanding company in the field of artificial intelligenceRanked on 「"Annual Most Commercially Valuable Enterprises" List。In 2024, the artificial intelligence industry is fully transitioning from foundational model research and development to application implementation. Represented by OpenAI's Sora multimodal technology, embodied intelligence has become the highlight of the year, leading the AI industry into a new phase of development. Amid this wave, large companies in China and independent developers are each playing to their strengths—major firms are heavily investing in AI assistants, image/video scenarios, while smaller teams are taking a global perspective to drive the rapid rise of innovative products.In this global AI technology competition, METiS TechBio, as a pioneer in the "AI + drug delivery" field, independently developed groundbreaking artificial intelligence and computational simulation algorithms from scratch despite challenges such as data scarcity and the absence of precedents for algorithms. These include algorithms for the generation and design of ionizable lipids and the design and simulation of LNP (lipid nanoparticles) nanomaterials. By integrating world-leading high-throughput experimental techniques with animal validation platforms, METiS TechBio has built a robust data and algorithmic barrier, achieving breakthrough progress in nanomaterial design and drug delivery.Moreover, by integrating the rapidly advancing large models and generative AI technologies, METiS TechBio has established the world's firstMETiS LipidLM Lipid Language ModelAndPhatGPT Lipid Generation Model, successfully building a million-level lipid library and breaking through international patent barriers. At the same time, METiS TechBio combines innovative molecular simulation technology to simulate various microscopic processes of LNP in vivo and in vitro, and relies on the world's top experimental verification platform to empower the development of multi-organ targeted nanomaterials, achieving the successful implementation of AI + nanomaterial applications.Hard But Right ThingThis is the theme of the WISE2024 Business King Conference. For enterprises, innovation is the core driving force for survival and development, as well as the ballast stone to deal with various uncertainties in the environment. However, this correct thing is easier said than done, requiring long-term investment and hands-on exploration.Looking ahead, METiS TechBio will continue to deepen its AI technology platform, empower the development of the pharmaceutical ecosystem, and explore broader AI application scenarios. The company will drive innovation through technology and benefit patients through innovation, committing to bring more breakthrough treatment solutions to patients worldwide and promote the high-quality development of the biopharmaceutical industry.About 「WISE2024 Business King Series Annual Enterprise Directory」In October this year, 36Kr officially launched the "WISE2024 Business King Series Annual Enterprise List" research. As the global economy calls for recovery, the focus is on discovering representative companies that provide innovative momentum for long-term industrial development and global economic growth. The list features two main categories: "WISE2024 Business King Annual Most Valuable Enterprise" and "WISE2024 Business King Annual Most Potential Enterprise," spanning nine new economic fields. After several rounds of selection from hundreds of nominated companies and incorporating insights from professional analysts, the "WISE2024 Business King Series Annual Enterprise List" is now officially released.
AttachmentAnnual Most Commercially Valuable Companies - AI List
Learn More About METiS TechBio
